Key takeaways
- The human MOTS-c studies discussed here measured levels of the peptide the body makes, rather than giving participants MOTS-c.
- The randomized elamipretide trial in 12 patients with Barth syndrome and its uncontrolled extension answer different questions.
- HHS names MOTS-c in a draft, non-binding compounding policy; FDA staff reported that neither its free base nor its acetate was an ingredient in an FDA-approved drug.
- WADA names MOTS-c in S4.4.1 and prohibits it at all times; SS-31 and elamipretide are not named on the 2026 or 2027 List, and we draw no sport-status conclusion of our own.
01MOTS-c vs SS-31 in one table
| Question | MOTS-c | SS-31 (elamipretide) |
|---|---|---|
| Identity | 16-amino-acid peptide encoded in the mitochondrial 12S rRNA region. | Synthetic four-amino-acid peptide that binds cardiolipin, a lipid in the inner mitochondrial membrane. |
| Evidence tier | T2 for measurements of natural levels in people; T3 for animal experiments and T4 for cell studies. These animal and cell studies are not evidence of an effect in people. | T1 for the randomized portion of TAZPOWER; T2 for its uncontrolled extension. Research-grade material labelled SS-31 is not the formulation studied. |
| Human data | Reynolds et al. (2021) measured natural levels in muscle and blood in 10 young men who cycled. FDA staff’s July 2026 review found no published study that gave MOTS-c to people. | TAZPOWER (2021 journal issue) measured six-minute walk distance and fatigue as its primary endpoints in 12 patients with Barth syndrome. The trial compared elamipretide with placebo, not MOTS-c. Research-grade material labelled SS-31 is not the formulation studied. |
| United States | FDA staff reported that neither the free base nor acetate was an ingredient in an FDA-approved drug. HHS names MOTS-c in its October 2026 draft, non-binding interim compounding policy. | FDA granted accelerated approval to Forzinity to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg, based on a change in knee extensor strength in an uncontrolled extension. Research-grade material labelled SS-31 is not that formulation. |
| United Kingdom | The emc medicines database returned no results for MOTS-c (21 November 2026); it is not the full UK register. | The emc medicines database returned no results for elamipretide or Forzinity (21 November 2026); it is not the full UK register. |
| Australia | The TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” MOTS-c has no entry by name in the October 2026 Poisons Standard; we draw no scheduling conclusion of our own. | We found no entry for SS-31 or elamipretide in the October 2026 Poisons Standard; we draw no scheduling conclusion of our own. |
| Sport | Named in WADA class S4.4.1, metabolic modulators, and prohibited at all times under both the 2026 and 2027 Lists. | SS-31 and elamipretide are not named on either List; we draw no sport-status conclusion of our own. |
02What differs at the molecular level?
If you searched “mots c vs ss 31”, start with what the term mitochondrial describes in each case.
MOTS-c: where the instructions are
The instructions for this 16-amino-acid peptide sit in a short stretch of mitochondrial DNA in the 12S rRNA region.
SS-31: what the peptide binds
Elamipretide is a synthetic peptide of four amino acids. The FDA label describes it as a binder of cardiolipin, a lipid in the inner mitochondrial membrane.
They share a research setting, not a molecular identity. Where a peptide is encoded and what another peptide binds are two different facts. Neither tells you how the two would compare on the same measure in the same people.
03What did the studies actually compare?
MOTS-c. In 2021, Reynolds and colleagues measured the body’s own MOTS-c in muscle and blood from 10 young men who cycled (T2). The researchers did not give the men the peptide. In the same paper, a separate experiment measured treadmill running time and distance in mice (T3; the middle-aged groups had 10 mice each, and the older groups had 18 and 19). The mouse experiment is not evidence of an effect in people. For more on the difference between natural levels and an administered compound, see the MOTS-c research guide.
Elamipretide. In TAZPOWER, published in the 2021 journal issue, each of the 12 patients with Barth syndrome received both elamipretide and placebo in separate periods, in a randomized sequence (T1). The FDA label says elamipretide was not superior to placebo on six-minute walk distance or the trial’s fatigue score. The label places the knee-strength finding in the later open-label extension, which 10 patients entered and which did not have a concurrent placebo group (T2). Research-grade material labelled SS-31 is not the formulation studied. Not medical advice.
04How did the U.S. regulatory paths differ?
- 19 September 2025FDA grants accelerated approval to Forzinity
The indication is to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. FDA based the decision on a change in knee extensor strength, an intermediate measure, and required a confirmatory trial to verify patient benefit. Research-grade material labelled SS-31 is not the approved formulation. Not medical advice.
- July 2026FDA staff and its advisory committee differ on MOTS-c
FDA staff recommended against listing the free base and acetate for section 503A compounding. HHS records that the committee voted in favour of listing both forms. An advisory recommendation is not a listing.
- 30 October 2026The Federal Register publishes notice of the HHS draft
The draft, non-binding interim policy names MOTS-c in Appendix A and describes when HHS does not intend to enforce against certain compounders. The notice says the draft “is not binding on HHS or the public”.
These records concern different decisions: one about a specific finished formulation and labelled population, the other about enforcement discretion for compounding. Neither determines what WADA lists. The 2026 Prohibited List is in force on 21 November 2026; the 2027 List comes into force on 1 January 2027.
05What we don't know
The human studies described here do not compare MOTS-c with elamipretide. Measuring a peptide already in the body cannot tell you what happens when it is given to someone. A placebo comparison for elamipretide in patients with Barth syndrome cannot answer that question for MOTS-c. These data do not support a verdict on which peptide is better.
Neither a study nor a regulatory record establishes what is in a particular research vial. For that narrower question, read the certificate of analysis, or COA, for the specific lot.
Check that the identifier on the report matches the identifier on the vial.
Look for the named peptide and the method used to identify it. A purity percentage alone does not distinguish MOTS-c from elamipretide.
Check what method produced the purity result. See how to read a COA for the difference between identity and purity.
This is a plain-English summary of public records and studies, dated 21 November 2026. It is not legal or medical advice.